CA2145192A1 - Novel epoxide-containing compounds - Google Patents

Novel epoxide-containing compounds

Info

Publication number: CA2145192A1
Authority: CA; Canada
Prior art keywords: mmol; yield; solution; added; water
Prior art date: 1992-09-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002145192A

Other languages

English (en)

French (fr)

Inventor

Gail Underiner

J. Peter Klein

John Michnick

Alistair Leigh

Anil Kumar

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

CTI Biopharma Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-22

Filing date

1993-09-22

Publication date

1994-03-31

1992-09-22 Priority claimed from US07/949,330 external-priority patent/US5288721A/en

1993-09-22 Application filed by Individual filed Critical Individual

1994-03-31 Publication of CA2145192A1 publication Critical patent/CA2145192A1/en

Status Abandoned legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 97
150000002118 epoxides Chemical class 0.000 title 1
150000003839 salts Chemical class 0.000 claims abstract description 10
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 4
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims abstract description 4
150000004677 hydrates Chemical class 0.000 claims abstract description 4
229960004559 theobromine Drugs 0.000 claims description 38
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 28
KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 claims description 23
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 21
125000000623 heterocyclic group Chemical group 0.000 claims description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 14
229940035893 uracil Drugs 0.000 claims description 14
-1 ortho-phenol Chemical compound 0.000 claims description 13
238000000034 method Methods 0.000 claims description 11
206010028980 Neoplasm Diseases 0.000 claims description 10
229940113082 thymine Drugs 0.000 claims description 10
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 9
239000011630 iodine Substances 0.000 claims description 9
229910052740 iodine Inorganic materials 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
229940024606 amino acid Drugs 0.000 claims description 8
235000001014 amino acid Nutrition 0.000 claims description 8
150000001413 amino acids Chemical class 0.000 claims description 8
201000010099 disease Diseases 0.000 claims description 8
206010040070 Septic Shock Diseases 0.000 claims description 7
208000035475 disorder Diseases 0.000 claims description 7
125000005843 halogen group Chemical group 0.000 claims description 7
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 6
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 6
238000011282 treatment Methods 0.000 claims description 6
150000001408 amides Chemical class 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical class C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims description 5
XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims description 5
238000002560 therapeutic procedure Methods 0.000 claims description 5
208000036142 Viral infection Diseases 0.000 claims description 4
208000026935 allergic disease Diseases 0.000 claims description 4
239000000460 chlorine Substances 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 4
230000036303 septic shock Effects 0.000 claims description 4
230000009385 viral infection Effects 0.000 claims description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 3
YTFXKURWTLWPKK-UHFFFAOYSA-N 1,3,5-triazinane-2,4-dione Chemical compound O=C1NCNC(=O)N1 YTFXKURWTLWPKK-UHFFFAOYSA-N 0.000 claims description 3
KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 3
LNDZXOWGUAIUBG-UHFFFAOYSA-N 6-aminouracil Chemical compound NC1=CC(=O)NC(=O)N1 LNDZXOWGUAIUBG-UHFFFAOYSA-N 0.000 claims description 3
201000004384 Alopecia Diseases 0.000 claims description 3
239000004475 Arginine Substances 0.000 claims description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
239000004471 Glycine Substances 0.000 claims description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
239000004472 Lysine Substances 0.000 claims description 3
208000012902 Nervous system disease Diseases 0.000 claims description 3
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
239000004473 Threonine Substances 0.000 claims description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
150000001412 amines Chemical class 0.000 claims description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
235000003704 aspartic acid Nutrition 0.000 claims description 3
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
229910052794 bromium Inorganic materials 0.000 claims description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
235000018417 cysteine Nutrition 0.000 claims description 3
230000002435 cytoreductive effect Effects 0.000 claims description 3
239000011737 fluorine Substances 0.000 claims description 3
229910052731 fluorine Inorganic materials 0.000 claims description 3
125000000524 functional group Chemical group 0.000 claims description 3
230000003676 hair loss Effects 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
230000028993 immune response Effects 0.000 claims description 3
229960000310 isoleucine Drugs 0.000 claims description 3
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 claims description 3
150000002576 ketones Chemical class 0.000 claims description 3
229930182817 methionine Natural products 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 3
208000037803 restenosis Diseases 0.000 claims description 3
229960002317 succinimide Drugs 0.000 claims description 3
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims description 3
125000003375 sulfoxide group Chemical group 0.000 claims description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
239000004474 valine Substances 0.000 claims description 3
229940075420 xanthine Drugs 0.000 claims description 3
DCGGMHIZEAHUJL-UHFFFAOYSA-N 1-methyl-1,3-diazinane-2,4,6-trione Chemical compound CN1C(=O)CC(=O)NC1=O DCGGMHIZEAHUJL-UHFFFAOYSA-N 0.000 claims description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
206010020772 Hypertension Diseases 0.000 claims description 2
206010061218 Inflammation Diseases 0.000 claims description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
206010028116 Mucosal inflammation Diseases 0.000 claims description 2
201000010927 Mucositis Diseases 0.000 claims description 2
229940076134 benzene Drugs 0.000 claims description 2
210000003169 central nervous system Anatomy 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
LOGSONSNCYTHPS-UHFFFAOYSA-N cyclopentane-1,3-dione Chemical compound O=C1CCC(=O)C1 LOGSONSNCYTHPS-UHFFFAOYSA-N 0.000 claims description 2
230000001747 exhibiting effect Effects 0.000 claims description 2
208000024963 hair loss Diseases 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
230000002519 immonomodulatory effect Effects 0.000 claims description 2
230000004054 inflammatory process Effects 0.000 claims description 2
201000008383 nephritis Diseases 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
238000011321 prophylaxis Methods 0.000 claims description 2
QGNQEODJYRGEJX-UHFFFAOYSA-N 4h-isoquinoline-1,3-dione Chemical compound C1=CC=C2C(=O)NC(=O)CC2=C1 QGNQEODJYRGEJX-UHFFFAOYSA-N 0.000 claims 2
PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 claims 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
206010053879 Sepsis syndrome Diseases 0.000 claims 2
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 1
NMIZONYLXCOHEF-UHFFFAOYSA-N 1h-imidazole-2-carboxamide Chemical compound NC(=O)C1=NC=CN1 NMIZONYLXCOHEF-UHFFFAOYSA-N 0.000 claims 1
YCQNXZAQYYNQTH-UHFFFAOYSA-N 2-methyl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CC1=NC=C2C=CNC2=N1 YCQNXZAQYYNQTH-UHFFFAOYSA-N 0.000 claims 1
CIFFBTOJCKSRJY-UHFFFAOYSA-N 3α,4,7,7α-tetrahydro-1h-isoindole-1,3(2h)-dione Chemical compound C1C=CCC2C(=O)NC(=O)C21 CIFFBTOJCKSRJY-UHFFFAOYSA-N 0.000 claims 1
CBQMKYHLDADRLN-UHFFFAOYSA-N 7-methylhypoxanthine Chemical compound N1C=NC(=O)C2=C1N=CN2C CBQMKYHLDADRLN-UHFFFAOYSA-N 0.000 claims 1
NJOYYTJYAMKQAG-UHFFFAOYSA-N 8-amino-3-methyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(C)C2=C1NC(N)=N2 NJOYYTJYAMKQAG-UHFFFAOYSA-N 0.000 claims 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
208000023275 Autoimmune disease Diseases 0.000 claims 1
SSQAEJTXAPEFJO-UHFFFAOYSA-N CC1(C=2C(=NC(=N1)O)C(=NN2)O)C Chemical compound CC1(C=2C(=NC(=N1)O)C(=NN2)O)C SSQAEJTXAPEFJO-UHFFFAOYSA-N 0.000 claims 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 1
229960003767 alanine Drugs 0.000 claims 1
235000004279 alanine Nutrition 0.000 claims 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
229960003121 arginine Drugs 0.000 claims 1
235000009697 arginine Nutrition 0.000 claims 1
229960001230 asparagine Drugs 0.000 claims 1
235000009582 asparagine Nutrition 0.000 claims 1
229960005261 aspartic acid Drugs 0.000 claims 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
229940054066 benzamide antipsychotics Drugs 0.000 claims 1
150000003936 benzamides Chemical class 0.000 claims 1
230000019522 cellular metabolic process Effects 0.000 claims 1
229960002433 cysteine Drugs 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
YVIVRJLWYJGJTJ-UHFFFAOYSA-N gamma-Valerolactam Chemical compound CC1CCC(=O)N1 YVIVRJLWYJGJTJ-UHFFFAOYSA-N 0.000 claims 1
229960002989 glutamic acid Drugs 0.000 claims 1
235000013922 glutamic acid Nutrition 0.000 claims 1
239000004220 glutamic acid Substances 0.000 claims 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
235000004554 glutamine Nutrition 0.000 claims 1
229960002743 glutamine Drugs 0.000 claims 1
229960002449 glycine Drugs 0.000 claims 1
230000003394 haemopoietic effect Effects 0.000 claims 1
229910052736 halogen Inorganic materials 0.000 claims 1
150000002367 halogens Chemical class 0.000 claims 1
229960002885 histidine Drugs 0.000 claims 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
208000027866 inflammatory disease Diseases 0.000 claims 1
229960003136 leucine Drugs 0.000 claims 1
229960003646 lysine Drugs 0.000 claims 1
229960004452 methionine Drugs 0.000 claims 1
150000004702 methyl esters Chemical class 0.000 claims 1
239000001301 oxygen Substances 0.000 claims 1
229960005190 phenylalanine Drugs 0.000 claims 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
229960002429 proline Drugs 0.000 claims 1
229960001153 serine Drugs 0.000 claims 1
206010040560 shock Diseases 0.000 claims 1
229960002898 threonine Drugs 0.000 claims 1
230000007675 toxicity by organ Effects 0.000 claims 1
231100000155 toxicity by organ Toxicity 0.000 claims 1
229960004799 tryptophan Drugs 0.000 claims 1
229960004441 tyrosine Drugs 0.000 claims 1
229960004295 valine Drugs 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 86
125000000217 alkyl group Chemical group 0.000 abstract description 7
239000012453 solvate Substances 0.000 abstract description 4
125000001475 halogen functional group Chemical group 0.000 abstract description 3
125000004430 oxygen atom Chemical group O* 0.000 abstract description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 238
239000000243 solution Substances 0.000 description 216
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 188
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 171
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 94
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 89
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 84
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 84
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 83
239000011541 reaction mixture Substances 0.000 description 81
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 80
239000002904 solvent Substances 0.000 description 79
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 73
238000003756 stirring Methods 0.000 description 73
239000007787 solid Substances 0.000 description 58
238000006243 chemical reaction Methods 0.000 description 57
210000004027 cell Anatomy 0.000 description 56
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 54
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
230000015572 biosynthetic process Effects 0.000 description 48
238000003786 synthesis reaction Methods 0.000 description 48
239000012044 organic layer Substances 0.000 description 47
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 45
229960001760 dimethyl sulfoxide Drugs 0.000 description 45
229910052938 sodium sulfate Inorganic materials 0.000 description 45
235000011152 sodium sulphate Nutrition 0.000 description 45
239000000741 silica gel Substances 0.000 description 43
229910002027 silica gel Inorganic materials 0.000 description 43
235000017557 sodium bicarbonate Nutrition 0.000 description 43
229910000030 sodium bicarbonate Inorganic materials 0.000 description 43
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 42
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
239000012043 crude product Substances 0.000 description 42
239000000284 extract Substances 0.000 description 42
230000002829 reductive effect Effects 0.000 description 41
229960001407 sodium bicarbonate Drugs 0.000 description 40
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 37
238000003818 flash chromatography Methods 0.000 description 37
239000012267 brine Substances 0.000 description 36
239000010410 layer Substances 0.000 description 36
239000012312 sodium hydride Substances 0.000 description 36
229910000104 sodium hydride Inorganic materials 0.000 description 36
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 36
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
108060008682 Tumor Necrosis Factor Proteins 0.000 description 32
229920006395 saturated elastomer Polymers 0.000 description 32
230000000694 effects Effects 0.000 description 31
239000003921 oil Substances 0.000 description 31
235000019198 oils Nutrition 0.000 description 31
102000003390 tumor necrosis factor Human genes 0.000 description 31
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
235000010265 sodium sulphite Nutrition 0.000 description 27
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 26
YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 26
229940079593 drug Drugs 0.000 description 23
239000003814 drug Substances 0.000 description 23
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 23
239000000725 suspension Substances 0.000 description 23
LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 22
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 21
230000035755 proliferation Effects 0.000 description 21
230000004044 response Effects 0.000 description 20
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 17
239000011734 sodium Substances 0.000 description 17
229910052708 sodium Inorganic materials 0.000 description 17
239000003208 petroleum Substances 0.000 description 16
239000012266 salt solution Substances 0.000 description 16
239000000377 silicon dioxide Substances 0.000 description 15
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 14
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 14
239000012230 colorless oil Substances 0.000 description 14
239000012074 organic phase Substances 0.000 description 14
238000000746 purification Methods 0.000 description 14
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 12
108010002350 Interleukin-2 Proteins 0.000 description 11
102000000588 Interleukin-2 Human genes 0.000 description 11
238000004587 chromatography analysis Methods 0.000 description 11
DGODWNOPHMXOTR-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium;dihydrate Chemical compound O.O.[K+].[K+].[O-][Os]([O-])(=O)=O DGODWNOPHMXOTR-UHFFFAOYSA-N 0.000 description 11
108010062580 Concanavalin A Proteins 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
230000004913 activation Effects 0.000 description 10
230000037361 pathway Effects 0.000 description 10
JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 10
230000000638 stimulation Effects 0.000 description 10
239000013078 crystal Substances 0.000 description 9
210000002889 endothelial cell Anatomy 0.000 description 9
229910000042 hydrogen bromide Inorganic materials 0.000 description 9
102000000589 Interleukin-1 Human genes 0.000 description 8
108010002352 Interleukin-1 Proteins 0.000 description 8
239000002253 acid Substances 0.000 description 8
238000004440 column chromatography Methods 0.000 description 8
239000007788 liquid Substances 0.000 description 8
239000012047 saturated solution Substances 0.000 description 8
OZHPKSFNBCNLER-UHFFFAOYSA-M sodium;3,7-dimethyl-6-oxopurin-2-olate Chemical compound [Na+].CN1C(=O)[N-]C(=O)C2=C1N=CN2C OZHPKSFNBCNLER-UHFFFAOYSA-M 0.000 description 8
RIMXEJYJXDBLIE-UHFFFAOYSA-N 6-bromohex-1-ene Chemical compound BrCCCCC=C RIMXEJYJXDBLIE-UHFFFAOYSA-N 0.000 description 7
241001674048 Phthiraptera Species 0.000 description 7
230000001413 cellular effect Effects 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 6
YPLVPFUSXYSHJD-UHFFFAOYSA-N 11-bromoundec-1-ene Chemical compound BrCCCCCCCCCC=C YPLVPFUSXYSHJD-UHFFFAOYSA-N 0.000 description 6
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
102000005741 Metalloproteases Human genes 0.000 description 6
108010006035 Metalloproteases Proteins 0.000 description 6
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
230000000735 allogeneic effect Effects 0.000 description 6
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 6
238000002512 chemotherapy Methods 0.000 description 6
231100000673 dose–response relationship Toxicity 0.000 description 6
239000005457 ice water Substances 0.000 description 6
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 6
230000003287 optical effect Effects 0.000 description 6
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 5
101710124165 1-acyl-sn-glycerol-3-phosphate acyltransferase Proteins 0.000 description 5
RQXPBVHYVAOUBY-UHFFFAOYSA-N 9-bromonon-1-ene Chemical compound BrCCCCCCCC=C RQXPBVHYVAOUBY-UHFFFAOYSA-N 0.000 description 5
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
208000009329 Graft vs Host Disease Diseases 0.000 description 5
101710097496 Lysophospholipid acyltransferase Proteins 0.000 description 5
102100038805 Lysophospholipid acyltransferase 2 Human genes 0.000 description 5
101710163746 Lysophospholipid acyltransferase 2 Proteins 0.000 description 5
101710172946 Probable 1-acyl-sn-glycerol-3-phosphate acyltransferase Proteins 0.000 description 5
230000001154 acute effect Effects 0.000 description 5
210000004271 bone marrow stromal cell Anatomy 0.000 description 5
238000010322 bone marrow transplantation Methods 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000006071 cream Substances 0.000 description 5
JMVOCSLPMGHXPG-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium Chemical compound [K+].[K+].[O-][Os]([O-])(=O)=O JMVOCSLPMGHXPG-UHFFFAOYSA-N 0.000 description 5
208000024908 graft versus host disease Diseases 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
230000002265 prevention Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
GKMIDMKPBOUSBQ-UHFFFAOYSA-N 1,5-dimethyluracil Chemical compound CC1=CN(C)C(=O)NC1=O GKMIDMKPBOUSBQ-UHFFFAOYSA-N 0.000 description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
108010081589 Becaplermin Proteins 0.000 description 4
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
239000012359 Methanesulfonyl chloride Substances 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
241000212342 Sium Species 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
230000001363 autoimmune Effects 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
239000007795 chemical reaction product Substances 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
150000004683 dihydrates Chemical class 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
210000004919 hair shaft Anatomy 0.000 description 4
230000011132 hemopoiesis Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
XBCXJKGHPABGSD-UHFFFAOYSA-N methyluracil Natural products CN1C=CC(=O)NC1=O XBCXJKGHPABGSD-UHFFFAOYSA-N 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
206010033675 panniculitis Diseases 0.000 description 4
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
239000004017 serum-free culture medium Substances 0.000 description 4
238000007390 skin biopsy Methods 0.000 description 4
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 4
229940001584 sodium metabisulfite Drugs 0.000 description 4
235000010262 sodium metabisulphite Nutrition 0.000 description 4
210000002536 stromal cell Anatomy 0.000 description 4
HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
BULBMIDMXFJDTE-UHFFFAOYSA-N 3-(5,6-dihydroxyhexyl)-1-methylpyrimidine-2,4-dione Chemical compound CN1C=CC(=O)N(CCCCC(O)CO)C1=O BULBMIDMXFJDTE-UHFFFAOYSA-N 0.000 description 3
BVCMFSVGOZXRAC-UHFFFAOYSA-N 3-(8,9-dihydroxynonyl)-1-methylpyrimidine-2,4-dione Chemical compound CN1C=CC(=O)N(CCCCCCCC(O)CO)C1=O BVCMFSVGOZXRAC-UHFFFAOYSA-N 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
102100020880 Kit ligand Human genes 0.000 description 3
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
102100026918 Phospholipase A2 Human genes 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
206010040047 Sepsis Diseases 0.000 description 3
108010039445 Stem Cell Factor Proteins 0.000 description 3
WBGHAFOUISIHKA-UHFFFAOYSA-N [1-bromo-9-(3-methyl-2,6-dioxopyrimidin-1-yl)nonan-2-yl] acetate Chemical compound CC(=O)OC(CBr)CCCCCCCN1C(=O)C=CN(C)C1=O WBGHAFOUISIHKA-UHFFFAOYSA-N 0.000 description 3
MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
238000003556 assay Methods 0.000 description 3
KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 3
239000001569 carbon dioxide Substances 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
230000021164 cell adhesion Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
230000036755 cellular response Effects 0.000 description 3
230000035605 chemotaxis Effects 0.000 description 3
GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 3
229940127089 cytotoxic agent Drugs 0.000 description 3
239000002158 endotoxin Substances 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
230000002538 fungal effect Effects 0.000 description 3
210000003630 histaminocyte Anatomy 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
229910000041 hydrogen chloride Inorganic materials 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
210000003810 lymphokine-activated killer cell Anatomy 0.000 description 3
IBMRTYCHDPMBFN-UHFFFAOYSA-N monomethyl glutaric acid Chemical compound COC(=O)CCCC(O)=O IBMRTYCHDPMBFN-UHFFFAOYSA-N 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
230000001473 noxious effect Effects 0.000 description 3
150000002924 oxiranes Chemical class 0.000 description 3
229920002866 paraformaldehyde Polymers 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
230000005855 radiation Effects 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
230000035939 shock Effects 0.000 description 3
239000008279 sol Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
QPKCDMXLSDFCQD-SNVBAGLBSA-N (6r)-8-bromo-2,6-dimethyloct-2-ene Chemical compound BrCC[C@H](C)CCC=C(C)C QPKCDMXLSDFCQD-SNVBAGLBSA-N 0.000 description 2
QPKCDMXLSDFCQD-JTQLQIEISA-N (6s)-8-bromo-2,6-dimethyloct-2-ene Chemical compound BrCC[C@@H](C)CCC=C(C)C QPKCDMXLSDFCQD-JTQLQIEISA-N 0.000 description 2
PPKPKFIWDXDAGC-IHWYPQMZSA-N (z)-1,2-dichloroprop-1-ene Chemical compound C\C(Cl)=C\Cl PPKPKFIWDXDAGC-IHWYPQMZSA-N 0.000 description 2
LLCJITKOWJMCQW-UHFFFAOYSA-N 1,5-dimethyl-3-non-8-enylpyrimidine-2,4-dione Chemical compound CC1=CN(C)C(=O)N(CCCCCCCC=C)C1=O LLCJITKOWJMCQW-UHFFFAOYSA-N 0.000 description 2
OZTIMDBJWPUDIU-UHFFFAOYSA-N 1-(5,6-dihydroxyhexyl)piperidine-2,6-dione Chemical compound OCC(O)CCCCN1C(=O)CCCC1=O OZTIMDBJWPUDIU-UHFFFAOYSA-N 0.000 description 2
FPIQGJUOIFYCFL-UHFFFAOYSA-N 1-methyl-3-non-8-enylpyrimidine-2,4-dione Chemical compound CN1C=CC(=O)N(CCCCCCCC=C)C1=O FPIQGJUOIFYCFL-UHFFFAOYSA-N 0.000 description 2
KVZJVHRBAVDLHC-UHFFFAOYSA-N 1-methyl-4a,5,6,7-tetrahydropteridine-2,4-dione Chemical compound N1CCN=C2N(C)C(=O)NC(=O)C21 KVZJVHRBAVDLHC-UHFFFAOYSA-N 0.000 description 2
ZMVPNTVKGZJNGM-UHFFFAOYSA-N 1-undec-10-enylpiperidine Chemical compound C=CCCCCCCCCCN1CCCCC1 ZMVPNTVKGZJNGM-UHFFFAOYSA-N 0.000 description 2
YHZVPUYIAMQPLW-UHFFFAOYSA-N 1-undec-10-enylpiperidine-2,6-dione Chemical compound C=CCCCCCCCCCN1C(=O)CCCC1=O YHZVPUYIAMQPLW-UHFFFAOYSA-N 0.000 description 2
PBIASHKZWUJPEI-UHFFFAOYSA-N 13-bromotridec-1-ene Chemical compound BrCCCCCCCCCCCC=C PBIASHKZWUJPEI-UHFFFAOYSA-N 0.000 description 2
NKRDOSWEUWAKQT-UHFFFAOYSA-N 3-hex-5-enyl-1,5-dimethylpyrimidine-2,4-dione Chemical compound CC1=CN(C)C(=O)N(CCCCC=C)C1=O NKRDOSWEUWAKQT-UHFFFAOYSA-N 0.000 description 2
STABAPSYCQFWOK-UHFFFAOYSA-N 4-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=C(Cl)C=C1 STABAPSYCQFWOK-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
210000003771 C cell Anatomy 0.000 description 2
241000283707 Capra Species 0.000 description 2
241000861718 Chloris <Aves> Species 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
102000004889 Interleukin-6 Human genes 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 2
108090000553 Phospholipase D Proteins 0.000 description 2
108010058864 Phospholipases A2 Proteins 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
108010004729 Phycoerythrin Proteins 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
206010044248 Toxic shock syndrome Diseases 0.000 description 2
231100000650 Toxic shock syndrome Toxicity 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
IPRCZJAWZJDLMU-UHFFFAOYSA-N [1-bromo-6-(3-methyl-2,6-dioxopyrimidin-1-yl)hexan-2-yl] acetate Chemical compound CC(=O)OC(CBr)CCCCN1C(=O)C=CN(C)C1=O IPRCZJAWZJDLMU-UHFFFAOYSA-N 0.000 description 2
XJGUKDJAOUXADK-UHFFFAOYSA-N [difluoro(naphthalen-2-yl)methyl]phosphonic acid Chemical compound C1=CC=CC2=CC(C(F)(F)P(O)(=O)O)=CC=C21 XJGUKDJAOUXADK-UHFFFAOYSA-N 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
229960003942 amphotericin b Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000003727 cerebral blood flow Effects 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
238000001816 cooling Methods 0.000 description 2
GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
230000034994 death Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000006735 deficit Effects 0.000 description 2
210000004207 dermis Anatomy 0.000 description 2
QNXYZQSFDTZEBK-UHFFFAOYSA-N dodec-11-en-1-ol Chemical compound OCCCCCCCCCCC=C QNXYZQSFDTZEBK-UHFFFAOYSA-N 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000001434 glomerular Effects 0.000 description 2
210000003780 hair follicle Anatomy 0.000 description 2
230000003779 hair growth Effects 0.000 description 2
VTIODUHBZHNXFP-UHFFFAOYSA-N hex-4-en-1-ol Chemical compound CC=CCCCO VTIODUHBZHNXFP-UHFFFAOYSA-N 0.000 description 2
ZHQLTKAVLJKSKR-UHFFFAOYSA-N homophthalic acid Chemical compound OC(=O)CC1=CC=CC=C1C(O)=O ZHQLTKAVLJKSKR-UHFFFAOYSA-N 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940100601 interleukin-6 Drugs 0.000 description 2
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
238000011580 nude mouse model Methods 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 2
229960001476 pentoxifylline Drugs 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
230000009696 proliferative response Effects 0.000 description 2
238000010791 quenching Methods 0.000 description 2
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229910021653 sulphate ion Inorganic materials 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
150000003509 tertiary alcohols Chemical class 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
AUSVLRIDVGJNPA-UHFFFAOYSA-N tridec-12-en-1-ol Chemical compound OCCCCCCCCCCCC=C AUSVLRIDVGJNPA-UHFFFAOYSA-N 0.000 description 2
210000003606 umbilical vein Anatomy 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
JSCUZAYKVZXKQE-JXMROGBWSA-N (2e)-1-bromo-3,7-dimethylocta-2,6-diene Chemical compound CC(C)=CCC\C(C)=C\CBr JSCUZAYKVZXKQE-JXMROGBWSA-N 0.000 description 1
VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
POFLOKMLBURRLA-LBPRGKRZSA-N (6s)-2,6-dimethyl-9-methylsulfonylnon-2-ene Chemical compound CS(=O)(=O)CCC[C@@H](C)CCC=C(C)C POFLOKMLBURRLA-LBPRGKRZSA-N 0.000 description 1
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
XJHRZBIBSSVCEL-ARJAWSKDSA-N (Z)-non-6-en-1-ol Chemical compound CC\C=C/CCCCCO XJHRZBIBSSVCEL-ARJAWSKDSA-N 0.000 description 1
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
WTRKPOLOMAGWIS-UHFFFAOYSA-N 1,5-dimethyl-3-undec-10-enylpyrimidine-2,4-dione Chemical compound CC1=CN(C)C(=O)N(CCCCCCCCCC=C)C1=O WTRKPOLOMAGWIS-UHFFFAOYSA-N 0.000 description 1
XQWBQQFNMPUBOP-UHFFFAOYSA-N 1-(10,11-dihydroxyundecyl)piperidin-2-one Chemical compound OCC(O)CCCCCCCCCN1CCCCC1=O XQWBQQFNMPUBOP-UHFFFAOYSA-N 0.000 description 1
AHXSEMZEFRDNCB-UHFFFAOYSA-N 1-(3,4-dihydroxybutyl)-3,7-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(CCC(O)CO)C(=O)C2=C1N=CN2C AHXSEMZEFRDNCB-UHFFFAOYSA-N 0.000 description 1
NSMXQKNUPPXBRG-UHFFFAOYSA-N 1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione Chemical group O=C1N(CCCCC(O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-UHFFFAOYSA-N 0.000 description 1
URARKVFKAIYYNF-UHFFFAOYSA-N 1-(6,7-dihydroxyheptyl)-3,7-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(CCCCCC(O)CO)C(=O)C2=C1N=CN2C URARKVFKAIYYNF-UHFFFAOYSA-N 0.000 description 1
PSCODLGAAGEJSG-UKTHLTGXSA-N 1-[(2e)-3,7-dimethylocta-2,6-dienyl]-3,7-dimethylpurine-2,6-dione Chemical compound O=C1N(C/C=C(C)/CCC=C(C)C)C(=O)N(C)C2=C1N(C)C=N2 PSCODLGAAGEJSG-UKTHLTGXSA-N 0.000 description 1
GLSQZRIALOVKTP-ZDUSSCGKSA-N 1-[(3s)-3,7-dimethyloct-6-enyl]-3,7-dimethylpurine-2,6-dione Chemical compound O=C1N(CC[C@H](CCC=C(C)C)C)C(=O)N(C)C2=C1N(C)C=N2 GLSQZRIALOVKTP-ZDUSSCGKSA-N 0.000 description 1
QTDDMPSIGTXOJL-CQSZACIVSA-N 1-[(4r)-4,8-dimethylnon-7-enyl]-3,7-dimethylpurine-2,6-dione Chemical compound O=C1N(CCC[C@H](C)CCC=C(C)C)C(=O)N(C)C2=C1N(C)C=N2 QTDDMPSIGTXOJL-CQSZACIVSA-N 0.000 description 1
LFBNUOZEQDEJHX-PZORYLMUSA-N 1-[(4r)-7,8-dihydroxy-4,8-dimethylnonyl]-3,7-dimethylpurine-2,6-dione Chemical compound O=C1N(CCC[C@@H](C)CCC(O)C(C)(C)O)C(=O)N(C)C2=C1N(C)C=N2 LFBNUOZEQDEJHX-PZORYLMUSA-N 0.000 description 1
QTDDMPSIGTXOJL-AWEZNQCLSA-N 1-[(4s)-4,8-dimethylnon-7-enyl]-3,7-dimethylpurine-2,6-dione Chemical compound O=C1N(CCC[C@@H](C)CCC=C(C)C)C(=O)N(C)C2=C1N(C)C=N2 QTDDMPSIGTXOJL-AWEZNQCLSA-N 0.000 description 1
102100031251 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Human genes 0.000 description 1
JTYUIAOHIYZBPB-UHFFFAOYSA-N 1-bromo-6-chlorohexane Chemical compound ClCCCCCCBr JTYUIAOHIYZBPB-UHFFFAOYSA-N 0.000 description 1
FBUZNPORDKVYFD-UHFFFAOYSA-N 1-bromohex-1-ene Chemical compound CCCCC=CBr FBUZNPORDKVYFD-UHFFFAOYSA-N 0.000 description 1
CZZZWEDUOMBCQE-UHFFFAOYSA-N 1-bromoundec-1-ene Chemical compound CCCCCCCCCC=CBr CZZZWEDUOMBCQE-UHFFFAOYSA-N 0.000 description 1
MWHSOEOFILFGNL-UHFFFAOYSA-N 1-undec-10-enylpiperidin-2-one Chemical compound C=CCCCCCCCCCN1CCCCC1=O MWHSOEOFILFGNL-UHFFFAOYSA-N 0.000 description 1
ALZKLNFAIMXPFW-UHFFFAOYSA-N 11-piperidin-1-ylundecane-1,2-diol Chemical compound OCC(O)CCCCCCCCCN1CCCCC1 ALZKLNFAIMXPFW-UHFFFAOYSA-N 0.000 description 1
VJPRDEURNGIXCJ-UHFFFAOYSA-N 12-methylsulfonyldodec-1-ene Chemical compound CS(=O)(=O)CCCCCCCCCCC=C VJPRDEURNGIXCJ-UHFFFAOYSA-N 0.000 description 1
SXYAPJBLESTMAX-UHFFFAOYSA-N 17-chloroheptadec-1-ene Chemical compound ClCCCCCCCCCCCCCCCC=C SXYAPJBLESTMAX-UHFFFAOYSA-N 0.000 description 1
UKUVVAMSXXBMRX-UHFFFAOYSA-N 2,4,5-trithia-1,3-diarsabicyclo[1.1.1]pentane Chemical compound S1[As]2S[As]1S2 UKUVVAMSXXBMRX-UHFFFAOYSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
108010054662 2-acylglycerophosphate acyltransferase Proteins 0.000 description 1
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
YOBYAKWFGPDGHG-UHFFFAOYSA-N 3,7-dimethyl-1-pent-4-enylpurine-2,6-dione Chemical compound CN1C(=O)N(CCCC=C)C(=O)C2=C1N=CN2C YOBYAKWFGPDGHG-UHFFFAOYSA-N 0.000 description 1
XUEJQUFGGVXJIA-UHFFFAOYSA-N 3,7-dimethyl-1-undec-10-enylpurine-2,6-dione Chemical compound CN1C(=O)N(CCCCCCCCCC=C)C(=O)C2=C1N=CN2C XUEJQUFGGVXJIA-UHFFFAOYSA-N 0.000 description 1
HHLMAQHFSUQAGL-UHFFFAOYSA-N 3-(5,6-dihydroxyhexyl)-1,5-dimethylpyrimidine-2,4-dione Chemical compound CC1=CN(C)C(=O)N(CCCCC(O)CO)C1=O HHLMAQHFSUQAGL-UHFFFAOYSA-N 0.000 description 1
UFJZYAGAUDNSEL-UHFFFAOYSA-N 3-(8,9-dihydroxynonyl)-1,5-dimethylpyrimidine-2,4-dione Chemical compound CC1=CN(C)C(=O)N(CCCCCCCC(O)CO)C1=O UFJZYAGAUDNSEL-UHFFFAOYSA-N 0.000 description 1
DXUMBAZRXSPFDZ-UHFFFAOYSA-N 3-hex-1-enyl-1-methylpyrimidine-2,4-dione Chemical compound CCCCC=CN1C(=O)C=CN(C)C1=O DXUMBAZRXSPFDZ-UHFFFAOYSA-N 0.000 description 1
PUXJALKHHNQPLJ-UHFFFAOYSA-N 3-hex-5-enyl-1-methylpyrimidine-2,4-dione Chemical compound CN1C=CC(=O)N(CCCCC=C)C1=O PUXJALKHHNQPLJ-UHFFFAOYSA-N 0.000 description 1
DMAYBPBPEUFIHJ-UHFFFAOYSA-N 4-bromobut-1-ene Chemical compound BrCCC=C DMAYBPBPEUFIHJ-UHFFFAOYSA-N 0.000 description 1
LPNANKDXVBMDKE-UHFFFAOYSA-N 5-bromopent-1-ene Chemical compound BrCCCC=C LPNANKDXVBMDKE-UHFFFAOYSA-N 0.000 description 1
UJPKUCMGPNZFOU-UHFFFAOYSA-N 6-bromonon-1-ene Chemical compound CCCC(Br)CCCC=C UJPKUCMGPNZFOU-UHFFFAOYSA-N 0.000 description 1
WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
XJHRZBIBSSVCEL-ONEGZZNKSA-N 6E-Nonen-1-ol Chemical compound CC\C=C\CCCCCO XJHRZBIBSSVCEL-ONEGZZNKSA-N 0.000 description 1
SNMOMUYLFLGQQS-UHFFFAOYSA-N 8-bromooct-1-ene Chemical compound BrCCCCCCC=C SNMOMUYLFLGQQS-UHFFFAOYSA-N 0.000 description 1
QGFSQVPRCWJZQK-UHFFFAOYSA-N 9-Decen-1-ol Chemical compound OCCCCCCCCC=C QGFSQVPRCWJZQK-UHFFFAOYSA-N 0.000 description 1
GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
206010000349 Acanthosis Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
241000256844 Apis mellifera Species 0.000 description 1
208000033116 Asbestos intoxication Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
206010063094 Cerebral malaria Diseases 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
241000207894 Convolvulus arvensis Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 description 1
208000001840 Dandruff Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
102100032484 Down syndrome critical region protein 8 Human genes 0.000 description 1
101100061188 Drosophila melanogaster dila gene Proteins 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
208000004145 Endometritis Diseases 0.000 description 1
208000037487 Endotoxemia Diseases 0.000 description 1
206010014824 Endotoxic shock Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
206010018634 Gouty Arthritis Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019728 Hepatitis alcoholic Diseases 0.000 description 1
101001016533 Homo sapiens Down syndrome critical region protein 8 Proteins 0.000 description 1
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
101000990912 Homo sapiens Matrilysin Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
101150037084 IMMT gene Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100025390 Integrin beta-2 Human genes 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
206010023203 Joint destruction Diseases 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
206010023330 Keloid scar Diseases 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
BUPJOLXWQXEJSQ-UHFFFAOYSA-N Lactifloreol Natural products C=C1CCC(C(C)C)=CC2C(O)(C)CCC21 BUPJOLXWQXEJSQ-UHFFFAOYSA-N 0.000 description 1
102100030417 Matrilysin Human genes 0.000 description 1
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000004140 Oncostatin M Human genes 0.000 description 1
108090000630 Oncostatin M Proteins 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
101710096328 Phospholipase A2 Proteins 0.000 description 1
102000011420 Phospholipase D Human genes 0.000 description 1
108010003541 Platelet Activating Factor Proteins 0.000 description 1
208000006399 Premature Obstetric Labor Diseases 0.000 description 1
206010036600 Premature labour Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
208000036741 Pruritus generalised Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
208000036071 Rhinorrhea Diseases 0.000 description 1
206010039101 Rhinorrhoea Diseases 0.000 description 1
101100408473 Rhodocybe pseudopiperita ple7 gene Proteins 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
201000002661 Spondylitis Diseases 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
101000585299 Tropidechis carinatus Acidic phospholipase A2 2 Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
206010062233 Uterine infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
XJHRZBIBSSVCEL-UHFFFAOYSA-N Z-Non-6-en-1-ol Natural products CCC=CCCCCCO XJHRZBIBSSVCEL-UHFFFAOYSA-N 0.000 description 1
AWVWHMFZFXJQJC-AFYYWNPRSA-N [(6r)-2-bromo-9-(3,7-dimethyl-2,6-dioxopurin-1-yl)-2,6-dimethylnonan-3-yl] acetate Chemical compound O=C1N(CCC[C@@H](C)CCC(OC(C)=O)C(C)(C)Br)C(=O)N(C)C2=C1N(C)C=N2 AWVWHMFZFXJQJC-AFYYWNPRSA-N 0.000 description 1
YHJIHYBLTKNKNA-UHFFFAOYSA-N [1-bromo-11-(2-oxopiperidin-1-yl)undecan-2-yl] acetate Chemical compound CC(=O)OC(CBr)CCCCCCCCCN1CCCCC1=O YHJIHYBLTKNKNA-UHFFFAOYSA-N 0.000 description 1
KHDGSVHYBYYLQX-UHFFFAOYSA-N [1-bromo-6-(3,5-dimethyl-2,6-dioxopyrimidin-1-yl)hexan-2-yl] acetate Chemical compound CC(=O)OC(CBr)CCCCN1C(=O)C(C)=CN(C)C1=O KHDGSVHYBYYLQX-UHFFFAOYSA-N 0.000 description 1
DPHZNAHLHICSBE-UHFFFAOYSA-N [1-bromo-9-(3,5-dimethyl-2,6-dioxopyrimidin-1-yl)nonan-2-yl] acetate Chemical compound CC(=O)OC(CBr)CCCCCCCN1C(=O)C(C)=CN(C)C1=O DPHZNAHLHICSBE-UHFFFAOYSA-N 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
208000002353 alcoholic hepatitis Diseases 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
108010022198 alkylglycerophosphoethanolamine phosphodiesterase Proteins 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
229940035678 anti-parkinson drug Drugs 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
206010003441 asbestosis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
230000006399 behavior Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000006652 catabolic pathway Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000010001 cellular homeostasis Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
150000001982 diacylglycerols Chemical class 0.000 description 1
FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229960002549 enoxacin Drugs 0.000 description 1
IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000003090 exacerbative effect Effects 0.000 description 1
150000002190 fatty acyls Chemical group 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
210000000224 granular leucocyte Anatomy 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000004349 growth plate Anatomy 0.000 description 1
229940124563 hair growth stimulant Drugs 0.000 description 1
UFULDTPDHIRNGS-UHFFFAOYSA-N hept-6-en-1-ol Chemical compound OCCCCCC=C UFULDTPDHIRNGS-UHFFFAOYSA-N 0.000 description 1
RYPKRALMXUUNKS-UHFFFAOYSA-N hex-2-ene Chemical compound CCCC=CC RYPKRALMXUUNKS-UHFFFAOYSA-N 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
150000003949 imides Chemical class 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229960003350 isoniazid Drugs 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
229960003404 mexiletine Drugs 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
229960003632 minoxidil Drugs 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
230000003843 mucus production Effects 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000021766 negative regulation of B cell proliferation Effects 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
229960001180 norfloxacin Drugs 0.000 description 1
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
229960001699 ofloxacin Drugs 0.000 description 1
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
108010036550 osteoclast activating factor Proteins 0.000 description 1
229960004236 pefloxacin Drugs 0.000 description 1
FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
239000008188 pellet Substances 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
230000003239 periodontal effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
108010017843 platelet-derived growth factor A Proteins 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
208000026440 premature labor Diseases 0.000 description 1
230000003658 preventing hair loss Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
208000028172 protozoa infectious disease Diseases 0.000 description 1
201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
230000002557 soporific effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
108091007196 stromelysin Proteins 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
210000003568 synaptosome Anatomy 0.000 description 1
210000002437 synoviocyte Anatomy 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
201000004647 tinea pedis Diseases 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000007838 tissue remodeling Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
229960005041 troleandomycin Drugs 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
PGNIFUDNBHMTPC-UHFFFAOYSA-N undec-10-ene-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCCCCCCC=C PGNIFUDNBHMTPC-UHFFFAOYSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
229930192406 valerol Natural products 0.000 description 1
230000006441 vascular event Effects 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pulmonology (AREA)
Virology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002145192A 1992-09-22 1993-09-22 Novel epoxide-containing compounds Abandoned CA2145192A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US07/949,330 US5288721A (en)	1992-09-22	1992-09-22	Substituted epoxyalkyl xanthines
US99165592A	1992-12-16	1992-12-16
US07/991,655		1992-12-16
US07/949,330		1992-12-16

Publications (1)

Publication Number	Publication Date
CA2145192A1 true CA2145192A1 (en)	1994-03-31

Family

ID=27130287

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002145192A Abandoned CA2145192A1 (en)	1992-09-22	1993-09-22	Novel epoxide-containing compounds

Country Status (5)

Country	Link
EP (1)	EP0662834A4 (ja)
JP (1)	JPH08501564A (ja)
AU (1)	AU5138493A (ja)
CA (1)	CA2145192A1 (ja)
WO (1)	WO1994006431A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0620739A4 (en) *	1992-09-15	1997-01-15	Immunex Corp	Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
US5446046A (en) *	1993-10-28	1995-08-29	University Of Florida Research Foundation	A1 adenosine receptor agonists and antagonists as diuretics
WO1995019171A1 (en) *	1994-01-14	1995-07-20	Cell Therapeutics, Inc.	Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
AU1967495A (en) *	1994-02-18	1995-09-04	Cell Therapeutics, Inc.	Intracellular signalling mediators
WO1998052919A1 (en) *	1997-05-21	1998-11-26	Japan Tobacco Inc.	Phthalimide derivatives and pharmaceutical containing said derivatives
US7276506B2 (en)	1998-12-28	2007-10-02	4 Aza Bioscience Nv	Immunosuppressive effects of pteridine derivatives
US6946465B2 (en)	1999-02-02	2005-09-20	4 Aza Bioscience Nv	Immunosuppressive effects of pteridine derivatives
WO2008009078A2 (en)	2006-07-20	2008-01-24	Gilead Sciences, Inc.	4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US10144736B2 (en)	2006-07-20	2018-12-04	Gilead Sciences, Inc.	Substituted pteridines useful for the treatment and prevention of viral infections
DK3097102T3 (en)	2015-03-04	2018-01-22	Gilead Sciences Inc	TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO [3,2-D] PYRIMIDINE COMPOUNDS
MA46093A (fr)	2016-09-02	2021-05-19	Gilead Sciences Inc	Composés modulateurs du recepteur de type toll
WO2018045150A1 (en)	2016-09-02	2018-03-08	Gilead Sciences, Inc.	4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
TW202212339A (zh)	2019-04-17	2022-04-01	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TW202210480A (zh)	2019-04-17	2022-03-16	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TWI879779B (zh)	2019-06-28	2025-04-11	美商基利科學股份有限公司	類鐸受體調節劑化合物的製備方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH472424A (de) *	1965-03-23	1969-05-15	Ciba Geigy	Verfahren zur Herstellung von neuen Polyepoxydverbindungen und deren Anwendung
US5158967A (en) *	1991-06-12	1992-10-27	E. R. Squibb & Sons, Inc.	7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease

1993
- 1993-09-22 WO PCT/US1993/009073 patent/WO1994006431A1/en not_active Ceased
- 1993-09-22 EP EP93922366A patent/EP0662834A4/en not_active Withdrawn
- 1993-09-22 CA CA002145192A patent/CA2145192A1/en not_active Abandoned
- 1993-09-22 AU AU51384/93A patent/AU5138493A/en not_active Abandoned
- 1993-09-22 JP JP6508445A patent/JPH08501564A/ja active Pending

Also Published As

Publication number	Publication date
EP0662834A4 (en)	1996-04-17
EP0662834A1 (en)	1995-07-19
AU5138493A (en)	1994-04-12
WO1994006431A1 (en)	1994-03-31
JPH08501564A (ja)	1996-02-20

Legal Events

Date	Code	Title	Description
1999-09-22	FZDE	Dead

Publication	Publication Date	Title
US6133274A (en)	2000-10-17	Hydroxyl-containing bicyclic compounds
US5670506A (en)	1997-09-23	Halogen, isothiocyanate or azide substituted xanthines
US5837703A (en)	1998-11-17	Amino-alcohol substituted cyclic compounds
US5817662A (en)	1998-10-06	Substituted amino alkyl compounds
EP0055583B1 (en)	1985-08-28	Antihypertensives
US3780040A (en)	1973-12-18	2-substituted-3,4-dihydroquinazolines
CA2117377C (en)	2006-05-30	Substituted amino alkyl compounds
US5777115A (en)	1998-07-07	Acetal-and ketal-substituted pyrimidine compounds
EP0746557A1 (en)	1996-12-11	Intracellular signalling mediators
US20010031760A1 (en)	2001-10-18	Method of treating a patient having precancerous lesions with quinazoline derivatives
CA2151617A1 (en)	1994-05-26	Hydroxyl-containing compounds
EP0662834A1 (en)	1995-07-19	Novel epoxide-containing compounds
EP0719267B1 (en)	2002-07-31	Second messenger cell signaling inhibitors
EP0608565A1 (en)	1994-08-03	Pyridopyrimidine derivatives, their production and use
US5801182A (en)	1998-09-01	Amine substituted compounds
JP2002509921A (ja)	2002-04-02	サイクリン依存性キナーゼ阻害剤
US5770595A (en)	1998-06-23	Oxime substituted therapeutic compounds
WO1994022863A9 (en)	1994-12-22	Second messenger cell signaling inhibitors
AU653601B2 (en)	1994-10-06	Pyrimidine derivatives for enhancing antitumor activity
US5866576A (en)	1999-02-02	Epoxide-containing compounds
WO1994024133A1 (en)	1994-10-27	Ring-substituted cell signaling inhibitors
JPH1017555A (ja)	1998-01-20	６−アミノ−５−メチルウラシル誘導体
US6103730A (en)	2000-08-15	Amine substituted compounds
EP0697873A1 (en)	1996-02-28	Olefin-substituted long chain compounds
AU9051898A (en)	1999-01-14	Second messenger cell signalling inhibitors